Leptin-based therapeutics

Expert Review of Endocrinology and Metabolism

Volumn 5, Issue 6, 2010, Pages 875-889

  Scolaro, Laura ^a   Cassone, Marco ^a   Kolaczynski, Jerzy W ^b   Otvos Jr , Laszlo ^a   Surmacz, Eva ^a  

^a TEMPLE UNIVERSITY   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

leptin; leptin mutants; peptide drugs; preclinical drug development

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; FLUOROURACIL; HORMONE RECEPTOR BLOCKING AGENT; LEPTIN; LEPTIN ANTAGONIST; RECOMBINANT LEPTIN; UNCLASSIFIED DRUG;

AMENORRHEA; BREAST CANCER; BREAST CARCINOGENESIS; CARDIOVASCULAR DISEASE; ENTERITIS; HORMONE BLOOD LEVEL; HORMONE DEFICIENCY; HORMONE RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEPTIN DEFICIENCY; LIPOATROPHY; LIPODYSTROPHY; NONHUMAN; OBESITY; OSTEOARTHRITIS; OSTEOPOROSIS; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETINOPATHY; REVIEW; SIGNAL TRANSDUCTION; WEIGHT CONTROL;

EID: 78649347074     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/eem.10.61     Document Type: Review

References (166)

1. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 372(6505), 425-432 (1994).
2. Huang L, Li C. Leptin: a multifunctional hormone. Cell Res. 10(2), 81-92 (2000).
3. Campfeld LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 269(5223), 546-549 (1995).
4. Harris RB, Zhou J, Redmann SM Jr et al. A leptin dose-response study in obese (ob/ob) and lean (+/?) mice. Endocrinology 139(1), 8-19 (1998).
5. Hsu A, Aronoff DM, Phipps J, Goel D, Mancuso P. Leptin improves pulmonary bacterial clearance and survival in ob/ob mice during pneumococcal pneumonia. Clin. Exp. Immunol. 150(2), 332-339 (2007).
6. Chehab FF, Lim ME, Lu R. Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat. Genet. 12(3), 318-320 (1996).
7. Zhang F, Basinski MB, Beals JM et al. Crystal structure of the obese protein leptin-E100. Nature 387(6629), 206-209 (1997).
8. Tartaglia LA. The leptin receptor. J. Biol. Chem. 272(10), 6093-6096 (1997).
9. Kastin AJ, Pan W, Maness LM, Koletsky RJ, Ernsberger P. Decreased transport of leptin across the blood-brain barrier in rats lacking the short form of the leptin receptor. Peptides 20(12), 1449-1453 (1999).
10. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 404(6778), 661-671 (2000).
11. Elias CF, Aschkenasi C, Lee C et al. Leptin differentially regulates NPY and POMC neurons projecting to the lateral hypothalamic area. Neuron 23(4), 775-786 (1999).
12. Ahima RS, Lazar MA. Adipokines and the peripheral and neural control of energy balance. Mol. Endocrinol. 22(5), 1023-1031 (2008).
13. Dyck DJ, Heigenhauser GJ, Bruce CR. The role of adipokines as regulators of skeletal muscle fatty acid metabolism and insulin sensitivity. Acta Physiol. (Oxf.) 186(1), 5-16 (2006).
14. Sweeney G. Cardiovascular effects of leptin. Nat. Rev. Cardiol. 7(1), 22-29 (2010).
15. Garofalo C, Surmacz E. Leptin and cancer. J. Cell. Physiol. 207(1), 12-22 (2006).
16. Wauters M, Considine RV, Van Gaal LF. Human leptin: from an adipocyte hormone to an endocrine mediator. Eur. J. Endocrinol. 143(3), 293-311 (2000).
17. Ducy P, Amling M, Takeda S et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100(2), 197-207 (2000).
18. Morton NM, Emilsson V, de Groot P, Pallett AL, Cawthorne MA. Leptin signalling in pancreatic islets and clonal insulin-secreting cells. J. Mol. Endocrinol. 22(2), 173-184 (1999).
19. Ring BD, Scully S, Davis CR et al. Systemically and topically administered leptin both accelerate wound healing in diabetic ob/ob mice. Endocrinology 141(1), 446-449 (2000).
20. Siegrist-Kaiser CA, Pauli V, Juge-Aubry CE et al. Direct effects of leptin on brown and white adipose tissue. J. Clin. Invest. 100(11), 2858-2864 (1997).
21. Kalra SP. Central leptin insuffciency syndrome: an interactive etiology for obesity, metabolic and neural diseases and for designing new therapeutic interventions. Peptides 29(1), 127-138 (2008).
22. Bado A, Levasseur S, Attoub S et al. The stomach is a source of leptin. Nature 394(6695), 790-793 (1998).
23. Wang J, Liu R, Hawkins M, Barzilai N, Rossetti L. A nutrient-sensing pathway regulates leptin gene expression in muscle and fat. Nature 393(6686), 684-688 (1998).
24. Masuzaki H, Ogawa Y, Sagawa N et al. Nonadipose tissue production of leptin: leptin as a novel placenta-derived hormone in humans. Nat. Med. 3(9), 1029-1033 (1997).
25. Hu X, Juneja SC, Maihle NJ, Cleary MP. Leptin-a growth factor in normal and malignant breast cells and for normal mammary gland development. J. Natl Cancer Inst. 94(22), 1704-1711 (2002).
26. Morash B, Li A, Murphy PR, Wilkinson M, Ur E. Leptin gene expression in the brain and pituitary gland. Endocrinology 140(12), 5995-5998 (1999).
27. Morash BA, Imran A, Wilkinson D, Ur E, Wilkinson M. Leptin receptors are developmentally regulated in rat pituitary and hypothalamus. Mol. Cell. Endocrinol. 210(1-2), 1-8 (2003).
28. Wilkinson M, Morash B, Ur E. The brain is a source of leptin. Front. Horm. Res. 26, 106-125 (2000).
29. Barr VA, Lane K, Taylor SI. Subcellular localization and internalization of the four human leptin receptor isoforms. J. Biol. Chem. 274(30), 21416-21424 (1999).
30. Dardeno TA, Chou SH, Moon HS, Chamberland JP, Fiorenza CG, Mantzoros CS. Leptin in human physiology and therapeutics. Front. Neuroendocrinol. 31(3), 377-393 (2010).
31. Lollmann B, Gruninger S, Stricker-Krongrad A, Chiesi M. Detection and quantifcation of the leptin receptor splice variants Ob-Ra, b, and, e in different mouse tissues. Biochem. Biophys. Res. Commun. 238(2), 648-652 (1997).
32. Fei H, Okano HJ, Li C et al. Anatomic localization of alternatively spliced leptin receptors (Ob-R) in mouse brain and other tissues. Proc. Natl Acad. Sci. USA 94(13), 7001-7005 (1997).
33. Lee GH, Proenca R, Montez JM et al. Abnormal splicing of the leptin receptor in diabetic mice. Nature 379(6566), 632-635 (1996).
34. Bjorbaek C, Buchholz RM, Davis SM et al. Divergent roles of SHP-2 in ERK activation by leptin receptors. J. Biol. Chem. 276(7), 4747-4755 (2001).
35. Villanueva EC, Myers MG Jr. Leptin receptor signaling and the regulation of mammalian physiology. Int. J. Obes. (Lond.) 32(Suppl. 7), S8-S12 (2008).
36. Sweeney G. Leptin signalling. Cell Signal. 14(8), 655-663 (2002).
37. Zabeau L, Lavens D, Peelman F, Eyckerman S, Vandekerckhove J, Tavernier J. The ins and outs of leptin receptor activation. FEBS Lett. 546(1), 45-50 (2003).
38. Zhang F, Chen Y, Heiman M, Dimarchi R. Leptin: structure, function and biology. Vitam. Horm. 71, 345-372 (2005).
39. Lim CT, Kola B, Korbonits M. AMPK as a mediator of hormonal signalling. J. Mol. Endocrinol. 44(2), 87-97 (2010).
40. Perera CN, Chin HG, Duru N, Camarillo IG. Leptin-regulated gene expression in MCF-7 breast cancer cells: mechanistic insights into leptin-regulated mammary tumor growth and progression. J. Endocrinol. 199(2), 221-233 (2008).
41. Saxena NK, Saliba G, Floyd JJ, Anania FA. Leptin induces increased a2(I) collagen gene expression in cultured rat hepatic stellate cells. J. Cell Biochem. 89(2), 311-320 (2003).
42. Han DC, Isono M, Chen S et al. Leptin stimulates type I collagen production in db/db mesangial cells: glucose uptake and TGF-b type II receptor expression. Kidney Int. 59(4), 1315-1323 (2001).
43. Frankenberry KA, Somasundar P, McFadden DW, Vona-Davis LC. Leptin induces cell migration and the expression of growth factors in human prostate cancer cells. Am. J. Surg. 188(5), 560-565 (2004).
44. Perera CN, Spalding HS, Mohammed SI, Camarillo IG. Identifcation of proteins secreted from leptin stimulated MCF-7 breast cancer cells: a dual proteomic approach. Exp. Biol. Med. (Maywood) 233(6), 708-720 (2008).
45. Gonzalez RR, Cherfls S, Escobar M et al. Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). J. Biol. Chem. 281(36), 26320-26328 (2006).
46. Cheng A, Uetani N, Simoncic PD et al. Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B. Dev. Cell 2(4), 497-503 (2002).
47. Zabolotny JM, Bence-Hanulec KK, Stricker-Krongrad A et al. PTP1B regulates leptin signal transduction in vivo. Dev. Cell 2(4), 489-495 (2002).
48. Farooqi IS. Monogenic human obesity. Front. Horm. Res. 36, 1-11 (2008).
49. Farooqi S, O'Rahilly S. Genetics of obesity in humans. Endocr. Rev. 27(7), 710-718 (2006).
50. Banks WA. Blood-brain barrier as a regulatory interface. Forum Nutr. 63, 102-110 (2010).
51. Kalra SP, Kalra PS. Neuroendocrine control of energy homeostasis: update on new insights. Prog. Brain Res. 181, 17-33 (2010).
52. Wilsey J, Scarpace PJ. Caloric restriction reverses the defcits in leptin receptor protein and leptin signaling capacity associated with diet-induced obesity: role of leptin in the regulation of hypothalamic long-form leptin receptor expression. J. Endocrinol. 181(2), 297-306 (2004).
53. Foster-Schubert KE, Cummings DE. Emerging therapeutic strategies for obesity. Endocr. Rev. 27(7), 779-793 (2006).
54. Chen K, Li F, Li J et al. Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat. Med. 12(4), 425-432 (2006).
55. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 50(3), 957-969 (2009).
56. Steinberg GR, McAinch AJ, Chen MB et al. The suppressor of cytokine signaling 3 inhibits leptin activation of AMP-kinase in cultured skeletal muscle of obese humans. J. Clin. Endocrinol. Metab. 91(9), 3592-3597 (2006).
57. Caro JF, Sinha MK, Kolaczynski JW, Zhang PL, Considine RV. Leptin: the tale of an obesity gene. Diabetes 45(11), 1455-1462 (1996).
58. Licinio J, Caglayan S, Ozata M et al. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-defcient adults. Proc. Natl Acad. Sci. USA 101(13), 4531-4536 (2004).
59. Dallongeville J, Hecquet B, Lebel P et al. Short term response of circulating leptin to feeding and fasting in man: infuence of circadian cycle. Int. J. Obes. Relat. Metab. Disord. 22(8), 728-733 (1998). (Pubitemid 28359286)
60. Kolaczynski JW, Considine RV, Ohannesian J et al. Responses of leptin to short-term fasting and refeeding in humans: a link with ketogenesis but not ketones themselves. Diabetes 45(11), 1511-1515 (1996).
61. Korner J, Inabnet W, Conwell IM et al. Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. Obesity (Silver Spring) 14(9), 1553-1561 (2006).
62. Geloneze B, Tambascia MA, Pareja JC, Repetto EM, Magna LA, Pereira SG. Serum leptin levels after bariatric surgery across a range of glucose tolerance from normal to diabetes. Obes. Surg. 11(6), 693-698 (2001).
63. Doucet E, Cameron J. Appetite control after weight loss: what is the role of bloodborne peptides? Appl. Physiol. Nutr. Metab. 32(3), 523-532 (2007).
64. Meguid MM, Glade MJ, Middleton FA. Weight regain after Roux-en-Y: a signifcant 20% complication related to PYY. Nutrition 24(9), 832-842 (2008).
65. Rosenbaum M, Goldsmith R, Bloomfeld D et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J. Clin. Invest. 115(12), 3579-3586 (2005).
66. Rosenbaum M, Sy M, Pavlovich K, Leibel RL, Hirsch J. Leptin reverses weight loss-induced changes in regional neural activity responses to visual food stimuli. J. Clin. Invest. 118(7), 2583-2591 (2008).
67. Capeau J, Magre J, Caron-Debarle M et al. Human lipodystrophies: genetic and acquired diseases of adipose tissue. Endocr. Dev. 19, 1-20 (2010).
68. Lee JH, Chan JL, Sourlas E, Raptopoulos V, Mantzoros CS. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profle in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J. Clin. Endocrinol. Metab. 91(7), 2605-2611 (2006).
69. Chong AY, Lupsa BC, Cochran EK, Gorden P. Effcacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia 53(1), 27-35 (2010).
70. Sweeney LL, Brennan AM, Mantzoros CS. The role of adipokines in relation to HIV lipodystrophy. AIDS 21(8), 895-904 (2007).
71. Oral EA, Chan JL. Rationale for leptin-replacement therapy for severe lipodystrophy. Endocr. Pract. 16(2), 324-333 (2010).
72. Kelesidis T, Kelesidis I, Chou S, Mantzoros CS. Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann. Intern. Med. 152(2), 93-100 (2010).
73. Brennan AM, Lee JH, Tsiodras S et al. r-metHuLeptin improves highly active antiretroviral therapy-induced lipoatrophy and the metabolic syndrome, but not through altering circulating IGF and IGF-binding protein levels: observational and interventional studies in humans. Eur. J. Endocrinol. 160(2), 173-176 (2009).
74. Gordon CM. Clinical practice. Functional hypothalamic amenorrhea. N. Engl. J. Med. 363(4), 365-371 (2010).
75. Genazzani AD, Chierchia E, Santagni S, Rattighieri E, Farinetti A, Lanzoni C. Hypothalamic amenorrhea: from diagnosis to therapeutical approach. Ann. Endocrinol. (Paris) 71(3), 163-169 (2010).
76. Bluher S, Mantzoros CS. Leptin in reproduction. Curr. Opin. Endocrinol. Diabetes Obes. 14(6), 458-464 (2007).
77. Hebebrand J, Muller TD, Holtkamp K, Herpertz-Dahlmann B. The role of leptin in anorexia nervosa: clinical implications. Mol. Psychiatry 12(1), 23-35 (2007).
78. Welt CK, Chan JL, Bullen J et al. Recombinant human leptin in women with hypothalamic amenorrhea. N. Engl. J. Med. 351(10), 987-997 (2004).
79. Reid IR, Ames R, Evans MC et al. Determinants of total body and regional bone mineral density in normal postmenopausal women-a key role for fat mass. J. Clin. Endocrinol. Metab. 75(1), 45-51 (1992).
80. Felson DT, Zhang Y, Hannan MT, Anderson JJ. Effects of weight and body mass index on bone mineral density in men and women: the Framingham study. J. Bone Miner. Res. 8(5), 567-573 (1993). (Pubitemid 23127916)
81. Elefteriou F, Ahn JD, Takeda S et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434(7032), 514-520 (2005).
82. Cirmanova V, Bayer M, Starka L, Zajickova K. The effect of leptin on bone: an evolving concept of action. Physiol. Res. 57(Suppl. 1), S143-S151 (2008).
83. Karsenty G. Convergence between bone and energy homeostases: leptin regulation of bone mass. Cell Metab. 4(5), 341-348 (2006).
84. Takeda S, Elefteriou F, Levasseur R et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 111(3), 305-317 (2002).
85. Yamagishi S, Amano S, Inagaki Y, Okamoto T, Takeuchi M, Inoue H. Pigment epithelium-derived factor inhibits leptin-induced angiogenesis by suppressing vascular endothelial growth factor gene expression through anti-oxidative properties. Microvasc. Res. 65(3), 186-190 (2003).
86. Cui JZ, Hornan D, Potter MJ et al. The role of leptin in choroidal neovascularization. Am. J. Ophthalmol. 132(5), 792-794 (2001).
87. Gariano RF, Nath AK, D'Amico DJ, Lee T, Sierra-Honigmann MR. Elevation of vitreous leptin in diabetic retinopathy and retinal detachment. Invest. Ophthalmol. Vis. Sci. 41(11), 3576-3581 (2000).
88. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 189(1), 47-60 (2006).
89. Hall JA, French TK, Rasmusson KD et al. The paradox of obesity in patients with heart failure. J. Am. Acad. Nurse Pract. 17(12), 542-546 (2005).
90. Arena R, Lavie CJ. The obesity paradox and outcome in heart failure: is excess bodyweight truly protective? Future Cardiol. 6(1), 1-6 (2010).
91. Edmonds S. Therapeutic targets for osteoarthritis. Maturitas 63(3), 191-194 (2009).
92. Magliano M. Obesity and arthritis. Menopause Int. 14(4), 149-154 (2008).
93. Otero M, Lago R, Gomez R et al. Towards a pro-infammatory and immunomodulatory emerging role of leptin. Rheumatology (Oxford) 45(8), 944-950 (2006).
94. Hu PF, Bao JP, Wu LD. The emerging role of adipokines in osteoarthritis: a narrative review. Mol. Biol. Rep. DOI: 10.1007/s11033-010-0179-y (2010) (Epub ahead of print).
95. Gomez R, Lago F, Gomez-Reino JJ, Gualillo O. Novel factors as therapeutic targets to treat diabetes. Focus on leptin and ghrelin. Expert Opin. Ther. Targets 13(5), 583-591 (2009).
96. Karmiris K, Koutroubakis IE, Kouroumalis EA. Leptin, adiponectin, resistin, and ghrelin-implications for infammatory bowel disease. Mol. Nutr. Food Res. 52(8), 855-866 (2008).
97. Harvie M, Hooper L, Howell AH. Central obesity and breast cancer risk: a systematic review. Obes. Rev. 4(3), 157-173 (2003).
98. Stephenson GD, Rose DP. Breast cancer and obesity: an update. Nutr. Cancer 45(1), 1-16 (2003).
99. Calle EE, Thun MJ. Obesity and cancer. Oncogene 23(38), 6365-6378 (2004).
100. Harvie M, Howell A. Energy balance adiposity and breast cancer-energy restriction strategies for breast cancer prevention. Obes. Rev. 7(1), 33-47 (2006).
101. Vona-Davis L, Howard-McNatt M, Rose DP. Adiposity, Type 2 diabetes and the metabolic syndrome in breast cancer. Obes. Rev. 8(5), 395-408 (2007).
102. Anderson AS, Caswell S. Obesity management-an opportunity for cancer prevention. Surgeon 7(5), 282-285 (2009).
103. Surmacz E. Obesity hormone leptin: a new target in breast cancer? Breast Cancer Res. 9(1), 301 (2007).
104. Fiorio E, Mercanti A, Terrasi M et al. Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivo analysis. BMC Cancer 8, 305 (2008).
105. Riolf M, Ferla R, Del Valle L et al. Leptin and its receptor are overexpressed in brain tumors and correlate with the degree of malignancy. Brain Pathol. 20(2), 481-489 (2010).
106. Koda M, Sulkowska M, Kanczuga-Koda L, Surmacz E, Sulkowski S. Overexpression of the obesity hormone leptin in human colorectal cancer. J. Clin. Pathol. 60(8), 902-906 (2007).
107. Wincewicz A, Koda M, Sulkowska M, Kanczuga-Koda L, Sulkowski S. Comparison of STAT3 with HIF-1a, Ob and ObR expressions in human endometrioid adenocarcinomas. Tissue Cell 40(6), 405-410 (2008).
108. Ellerhorst JA, Diwan AH, Dang SM et al. Promotion of melanoma growth by the metabolic hormone leptin. Oncol. Rep. 23(4), 901-907 (2010).
109. Garofalo C, Sisci D, Surmacz E. Leptin interferes with the effects of the antiestrogen ICI 182,780 in MCF-7 breast cancer cells. Clin. Cancer Res. 10(19), 6466-6475 (2004).
110. Soma D, Kitayama J, Yamashita H, Miyato H, Ishikawa M, Nagawa H. Leptin augments proliferation of breast cancer cells via transactivation of HER2. J. Surg. Res. 149(1), 9-14 (2007).
111. Saxena NK, Taliaferro-Smith L, Knight BB et al. Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Res. 68(23), 9712-9722 (2008).
112. Bartucci M, Svensson S, Ricci-Vitiani L et al. Obesity hormone leptin induces growth and interferes with the cytotoxic effects of 5-fuorouracil in colorectal tumor stem cells. Endocr. Relat. Cancer 17(3), 823-833 (2010).
113. Cleary MP, Phillips FC, Getzin SC et al. Genetically obese MMTV-TGF-a/Lep(ob) Lep(ob) female mice do not develop mammary tumors. Breast Cancer Res. Treat. 77(3), 205-215 (2003).
114. Cleary MP, Grande JP, Juneja SC, Maihle NJ. Diet-induced obesity and mammary tumor development in MMTV-neu female mice. Nutr. Cancer 50(2), 174-180 (2004).
115. Otvos L Jr, Kovalszky I, Scolaro L et al. Peptide-based leptin receptor antagonists for cancer treatment and appetite regulation. Biopolymers DOI: 10.1002/bip.21377 (2010) (Epub ahead of print).
116. Lemoine M, Ratziu V, Kim M et al. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int. 29(9), 1431-1438 (2009).
117. Tsochatzis EA, Papatheodoridis GV, Archimandritis AJ. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Infamm. 831670, (2009) (Abstract).
118. Hindle AK, Edwards C, Mendonsa A et al. Adiponectin but not leptin is involved in early hepatic disease in morbidly obese patients. Surg. Endosc. 24(7), 1547-1551 (2010).
119. Aguilar-Chavez EA, Gamez-Nava JI, Lopez-Olivo MA et al. Circulating leptin and bone mineral density in rheumatoid arthritis. J. Rheumatol. 36(3), 512-516 (2009).
120. Wislowska M, Rok M, Jaszczyk B, Stepien K, Cicha M. Serum leptin in rheumatoid arthritis. Rheumatol. Int. 27(10), 947-954 (2007).
121. Salazar-Paramo M, Gonzalez-Ortiz M, Gonzalez-Lopez L et al. Serum leptin levels in patients with rheumatoid arthritis. J. Clin. Rheumatol. 7(1), 57-59 (2001).
122. Otero M, Lago R, Gomez R, Lago F, Gomez-Reino JJ, Gualillo O. Leptin: a metabolic hormone that functions like a proinfammatory adipokine. Drug News Perspect. 19(1), 21-26 (2006).
123. Palmer G, Gabay C. A role for leptin in rheumatic diseases? Ann. Rheum. Dis. 62(10), 913-915 (2003).
124. Weng Z, Signore A P, Gao Y et al. Leptin protects against 6-hydroxydopamine-induced dopaminergic cell death via mitogen-activated protein kinase signaling. J. Biol. Chem. 282(47), 34479-34491 (2007).
125. Lu XY, Kim CS, Frazer A, Zhang W. Leptin: a potential novel antidepressant. Proc. Natl Acad. Sci. USA 103(5), 1593-1598 (2006).
126. Cai C, Shi FD, Matarese G, La Cava A. Leptin as clinical target. Recent Pat. Infamm. Allergy Drug Discov. 3(3), 160-166 (2009).
127. Kos K, Wilding JP. Adipokines: emerging therapeutic targets. Curr. Opin. Investig. Drugs 10(10), 1061-1068 (2009).
128. Varnerin JP, Smith T, Rosenblum CI et al. Production of leptin in Escherichia coli: a comparison of methods. Protein Expr. Purif. 14(3), 335-342 (1998).
129. Salvador J, Gomez-Ambrosi J, Fruhbeck G. Perspectives in the therapeutic use of leptin. Expert Opin. Pharmacother. 2(10), 1615-1622 (2001).
130. Hamann A, Matthaei S. Regulation of energy balance by leptin. Exp. Clin. Endocrinol. Diabetes 104(4), 293-300 (1996).
131. Nagao K, Inoue N, Ujino Y et al. Effect of leptin infusion on insulin sensitivity and lipid metabolism in diet-induced lipodystrophy model mice. Lipids Health Dis. 7, 8 (2008).
132. Savage DB. Mouse models of inherited lipodystrophy. Dis. Model. Mech. 2(11-12), 554-562 (2009).
133. Farooqi IS, Jebb SA, Langmack G et al. Effects of recombinant leptin therapy in a child with congenital leptin defciency. N. Engl. J. Med. 341(12), 879-884 (1999).
134. Farooqi IS, O'Rahilly S. Leptin: a pivotal regulator of human energy homeostasis. Am. J. Clin. Nutr. 89(3), 980S-984S (2009).
135. Gibson W T, Farooqi IS, Moreau M et al. Congenital leptin defciency due to homozygosity for the d133G mutation: report of another case and evaluation of response to four years of leptin therapy. J. Clin. Endocrinol. Metab. 89(10), 4821-4826 (2004).
136. Heymsfeld SB, Greenberg AS, Fujioka K et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 282(16), 1568-1575 (1999).
137. Oral EA, Simha V, Ruiz E et al. Leptin-replacement therapy for lipodystrophy. N. Engl. J. Med. 346(8), 570-578 (2002).
138. Javor ED, Cochran EK, Musso C, Young JR, Depaoli AM, Gorden P. Long-term effcacy of leptin replacement in patients with generalized lipodystrophy. Diabetes 54(7), 1994-2002 (2005).
139. Hukshorn CJ, Menheere PP, Westerterp-Plantenga MS, Saris WH. The effect of pegylated human recombinant leptin (PEG-OB) on neuroendocrine adaptations to semi-starvation in overweight men. Eur. J. Endocrinol. 148(6), 649-655 (2003).
140. Hukshorn CJ, Westerterp-Plantenga MS, Saris WH. Pegylated human recombinant leptin (PEG-OB) causes additional weight loss in severely energy-restricted, overweight men. Am. J. Clin. Nutr. 77(4), 771-776 (2003).
141. Lejeune MP, Hukshorn CJ, Saris WH, Westerterp-Plantenga MS. Effect of dietary restraint during and following pegylated recombinant leptin (PEG-OB) treatment of overweight men. Int. J. Obes. Relat. Metab. Disord. 27(12), 1494-1499 (2003).
142. Zelissen PM, Stenlof K, Lean ME et al. Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial. Diabetes Obes. Metab. 7(6), 755-761 (2005).
143. Gertler A. Development of leptin antagonists and their potential use in experimental biology and medicine. Trends Endocrinol. Metab. 17(9), 372-378 (2006).
144. Verploegen SA, Plaetinck G, Devos R, Van der Heyden J, Guisez Y. A human leptin mutant induces weight gain in normal mice. FEBS Lett. 405(2), 237-240 (1997).
145. Elinav E, Niv-Spector L, Katz M et al. Pegylated leptin antagonist is a potent orexigenic agent: preparation and mechanism of activity. Endocrinology 150(7), 3083-3091 (2009).
146. Salomon G, Niv-Spector L, Gussakovsky EE, Gertler A. Large-scale preparation of biologically active mouse and rat leptins and their L39A/D40A/F41A muteins which act as potent antagonists. Protein Expr. Purif. 47(1), 128-136 (2006).
147. Solomon G, Niv-Spector L, Gonen-Berger D, Callebaut I, Djiane J, Gertler A. Preparation of leptin antagonists by site-directed mutagenesis of human, ovine, rat, and mouse leptin's site III: implications on blocking undesired leptin action in vivo. Ann. NY Acad. Sci. 1091, 531-539 (2006).
148. Niv-Spector L, Gonen-Berger D, Gourdou I et al. Identifcation of the hydrophobic strand in the A-B loop of leptin as major binding site III: implications for large-scale preparation of potent recombinant human and ovine leptin antagonists. Biochem. J. 391(Pt 2), 221-230 (2005).
149. Raver N, Vardy E, Livnah O, Devos R, Gertler A. Comparison of R128Q mutations in human, ovine, and chicken leptins. Gen. Comp. Endocrinol. 126(1), 52-58 (2002).
150. Otvos L Jr, Cassone M, Terrasi M et al. Agonists and partial antagonists acting on the leptin-leptin receptor interface. Adv. Exp. Med. Biol. 611, 497-498 (2009).
151. Otvos L Jr, Terrasi M, Cascio S et al. Development of a pharmacologically improved peptide agonist of the leptin receptor. Biochim. Biophys. Acta 1783(10), 1745-1754 (2008).
152. Gonzalez RR, Leavis PC. A peptide derived from the human leptin molecule is a potent inhibitor of the leptin receptor function in rabbit endometrial cells. Endocrine 21(2), 185-195 (2003).
153. Gonzalez RR, Rueda BR, Ramos MP, Littell RD, Glasser S, Leavis PC. Leptin-induced increase in leukemia inhibitory factor and its receptor by human endometrium is partially mediated by interleukin 1 receptor signaling. Endocrinology 145(8), 3850-3857 (2004).
154. Ramos MP, Rueda BR, Leavis PC, Gonzalez RR. Leptin serves as an upstream activator of an obligatory signaling cascade in the embryo-implantation process. Endocrinology 146(2), 694-701 (2005).
155. Rene Gonzalez R, Watters A, Xu Y et al. Leptin-signaling inhibition results in effcient anti-tumor activity in estrogen receptor positive or negative breast cancer. Breast Cancer Res. 11(3), R36 (2009).
156. Grasso P, White DW, Tartaglia LA, Leinung MC, Lee DW. Inhibitory effects of leptin-related synthetic peptide 116-130 on food intake and body weight gain in female C57BL/6J ob/ob mice may not be mediated by peptide activation of the long isoform of the leptin receptor. Diabetes 48(11), 2204-2209 (1999).
157. Grasso P, Leinung MC, Ingher SP, Lee DW. In vivo effects of leptin-related synthetic peptides on body weight and food intake in female ob/ob mice: localization of leptin activity to domains between amino acid residues 106-140. Endocrinology 138(4), 1413-1418 (1997).
158. Hardwick JC, Van Den Brink GR, Offerhaus GJ, Van Deventer SJ, Peppelenbosch MP. Leptin is a growth factor for colonic epithelial cells. Gastroenterology 121(1), 79-90 (2001).
159. Rozhavskaya-Arena M, Lee DW, Leinung MC, Grasso P. Design of a synthetic leptin agonist: effects on energy balance, glucose homeostasis, and thermoregulation. Endocrinology 141(7), 2501-2507 (2000).
160. Lee DW, Leinung MC, Grasso P. The effects of age on uptake, serum half-life and bioavailability of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, in male C57BL/6J mice. Regul. Pept. 150(1-3), 62-65 (2008).
161. Kovalszky I, Surmacz E, Scolaro L et al. Leptin-based glycopeptide induces weight loss and simultaneously restores fertility in animal models. Diabetes Obes. Metab. 12(5), 393-402 (2010).
162. Fazeli M, Zarkesh-Esfahani H, Wu Z et al. Identifcation of a monoclonal antibody against the leptin receptor that acts as an antagonist and blocks human monocyte and T cell activation. J. Immunol. Methods 312(1-2), 190-200 (2006).
163. Zeidan A, Purdham DM, Rajapurohitam V, Javadov S, Chakrabarti S, Karmazyn M. Leptin induces vascular smooth muscle cell hypertrophy through angiotensin II-and endothelin-1-dependent mechanisms and mediates stretch-induced hypertrophy. J. Pharmacol. Exp. Ther. 315(3), 1075-1084 (2005).
164. Zeidan A, Javadov S, Chakrabarti S, Karmazyn M. Leptin-induced cardiomyocyte hypertrophy involves selective caveolae and RhoA/ROCK-dependent p38 MAPK translocation to nuclei. Cardiovasc. Res. 77(1), 64-72 (2008).
165. Peelman F, Van Beneden K, Zabeau L et al. Mapping of the leptin binding sites and design of a leptin antagonist. J. Biol. Chem. 279(39), 41038-41046 (2004).
166. Otvos L Jr, Cassone M, Wade J et al. Peptides 2008. Proceedings of the 30th European Peptide Symposium. In: Finnish Peptide Society. Lankinen H (Ed.). Helsinki, Finland, 436-437 (2009).